BRIEF-Amgen, Harvard Pilgrim agree to contract for repatha
May 2 Amgen Inc:
* Amgen and Harvard Pilgrim agree to first cardiovascular outcomes-based refund contract for repatha (evolocumab)
* Amgen - contract provides Harvard Pilgrim with a rebate for cost of repatha for an eligible patient who has a heart attack or stroke while on repatha Source text for Eikon: Further company coverage: